The FDA said it received multiple reports that the baby formula is still being found on store shelves in multiple states.
Flow Space on MSN
Update: FDA Removes Black-Box Warning From Menopause Hormone Therapy Drugs After Expert Panel Recommendation
The U.S. Food and Drug Administration (FDA) announced today that it’s recommending the removal of black-box warnings, the ...
Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...
9don MSN
The FDA Just Announced A Major Update On Hormone Therapy In The U.S. Here's What It Means For You
Hormone therapy (HT) is a treatment used for symptoms of menopause, according to the American College of Obstetricians and ...
The Associated Press on MSN
The FDA removes a long-standing warning from hormone-based menopause drugs
Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about ...
On July 29, 2025, the U.S. Food and Drug Administration (FDA) announced its recommendation to schedule 7-hydroxymitragynine (7-OH)—a concentrated byproduct of the kratom plant—under the Controlled ...
FDA issues Class II recall for ADHD drug after quality concerns, with millions of prescriptions potentially impacted.
This action follows reports of 15 suspected or confirmed cases of infant botulism across 12 states as of Monday, the FDA says ...
FDA's release of CRLs for unapproved products does not appear to be limited to situations where the application's existence had been publicly disclosed or acknowledged. Based on our review of those ...
Vyjuvek (beremagene geperpavec-svdt) is the first topical gene therapy approved to heal wounds in adults and children with dystrophic epidermolysis bullosa (DEB). DEB is a rare genetic skin condition ...
uniQure expects to receive final minutes within 30 days of the meeting and plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of AMT-130.
WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results